诊疗流程（图 7-1）
图 7-1 ANCA 相关血管炎诊疗流程
参考文献 [1] HAO J, WANG C, YUAN J, e t a l. A pro-inflammatory
role of C5L2 in C5a –primed neutrophils for ANCA-induced activation. PLoS One
,2013,8(6):e66305. [2] SÖDERBERG D, SEGELMARK M. Neutrophil extracellula
r traps in vasculitis, friend or foe ? . Curr Opin Rheuma tol,2018,30(1):16-23.
[3] MUKHTYAR C, GUILLEVIN L, CID MC, e t a l. EULAR re
commendations for the management of prima rysmall and medium vessel vasculitis.
Ann Rheum Dis,2009,68(3):310-317.39 [4] ELEFANTE E, BOND M, MONTI S, etal. One ye a r in
review 2018: systemic vasculitis. Clin Exp Rheumatol,2018,36 Suppl
111(2):12-32. [5] LI J, ZHU M, LI M, e t a l. Cause of death in
Chinese Takayasu arteritis patients. Medicine (Baltimore ),2016,95(27):e4069. [6] NAGASE H, UEKI S, FUJIEDA S. The role s of IL-5
and anti-IL-5 treatment in eosinophilic diseases: asthma , eosinophilic
granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol
Int,2020,69(2):178-186. [7] VARRICCHI G, BAGNASCO D, BORRIELLO F, etal. Interleukin-5
pathway inhibition in the treatment of eosinophilicre spiratory disorders:
evidence and unmet needs. Curr Opin Allergy Clin Immunol,2016,16(2):186-200. [8] GEETHA D, JEFFERSON JA. ANCA-a ssociated vasculitis:
core curriculum 2020. Am J Kidney Dis,2020,75(1):124-137. [9] HASSANI M, KOENDERMAN L. Immunological and hematologica
l effects of IL-5(R α)-targeted therapy: An overview. Allergy,2018,73(10):1979-1988.
[10] GAPUD EJ, SEO P, ANTIOCHOS B. ANCA-associated vasculitis
pathogenesis: a commentary. Curr Rheumatol Rep,2017,19(4):15-33. [11] NISHI R, KOIKE H, OHYAMA K, etal. Association between
IL-5 Levels and the clinicopa thologic features of eosinophilic granulomatosis
with polyangiitis. Neurology,2021,96(5):226-229. [12] MERINO-VICO A, VAN HAMBURG JP, TAS SW. B line age
ce lls in ANCA-a ssociated vasculitis. Int J Mol Sci,2021,23(1):387. [13] PARK HJ, JUNG SM, SONG JJ, etal. Comparison of radiological
and histological findings of lung parenchyma in patients with antineutrophil
cytoplasmic antibody-associated vasculitis. Yonse i Med J,2019,60(5):454-460. [14] UENO M, MIYAGAWA I, NAKANO K, etal. Effectivene
ss and safety of mepolizumab in combination with corticosteroids in patients
with eosinophilic granulomatosis with polyangiitis. Arthritis Re s The
r,2021,23:86-95. [15] SCOTT J, HARTNETT J, MOCKLER D, etal.
Environmental risk factors associated with ANCA associated vasculitis: a
systematic mapping review. Autoimmun Rev, 2020,19(11):102660. [16] LYONS PA, SMITH KG. L31. a GWAS in ANCA-a ssociated
vasculitis: will genetics help re-define clinical classification? . Presse
Med,2013,42(4 Pt 2):589-591. [17] KRONBICHLER A, LEE KH, DENICOLÒ S, etal. Immunopathogenesis
of ANCA-a ssocia ted vasculitis. Int J Mol Sci,2020,21(19):7319. [18] NAKAZAWA D, MASUDA S, TOMARU U, etal. Pathogene
sis and therapeutic interventions for ANCA-associated vasculitis. Na t Rev
Rheumatol,2019,15(2):91-101. [19] ALBA MA, JENNETTE JC, FALK RJ. Pathogenesis of
ANCA-associated pulmonary vasculitis. Semin Respir Crit Care
Med,2018,39(4):413-424. [20] FERRARIO F, VANZATI A, PAGNI F, etal. Pathology
of ANCA-associated vasculitis. Clin Exp Nephrol,2013,17:652–658. [21] SMITH ML. Pathology of antineutrophil cytopla smic antibody-associated pulmonary and renal disease . Arch Pathol Lab Med,2017,141(2):223-231. |
